Pancreatic cancer has high rate of failures in late-stage clinical trials
The pancreatic cancer market has fewer competitors than most cancer markets, despite being one of the most challenging forms of cancer to treat, notes a new report from GlobalData, titled Pancreatic Cancer - Drug Pipeline Analysis and Martket Forecasts to 2016.
The reason for this is the high incidence of failures in late stage clinical trials. In 2005, Supergen withdrew a filing for Orathecin (rubitecan) as the data was insufficient to gain approval. Aphton also announced that its drug Insegia (G17DT immunogen) failed to meet its primary endpoint in the Phase III trial. GenVac announced the failure of TNFerade in 2010. Because of the immediate need for treatment, the Food and Drug Administration has deemed drugs and therapeutics for pancreatic cancer eligible for Fast Track designations.
Gemzar remains treatment of choice, but is set to see generic erosion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze